Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Dose-dependent side effects related to myo-inositol (MI) oral administration represent a significant shortcoming for its clinical use. Aiming to search for a pharmaceutical form able to be better absorbed, the pharmacokinetic (PK) profile of the new manufactured MI soft gelatin capsule form was evaluated and compared with the commercially available MI powder. RESEARCH DESIGN AND METHODS: A single-dose relative trial, consisting of four phases, was performed on 20 healthy volunteers who received different doses of MI powder and MI soft gelatin capsules. PK profiles related to the two pharmaceutical forms were obtained by analysis of MI plasma concentration, and the respective MI bioavailability was compared. RESULTS: The administration of MI powder and MI soft gelatin capsules resulted in a different bioavailability. MI soft gelatin capsule form showed similar PK parameters compared with three times higher doses of MI in powder form. CONCLUSIONS: MI soft gelatin capsules displayed an improved bioavailability, allowing to substantially reduce the administered dose and to minimize the dose-dependent side effects. Considering the number of conditions in which MI supplementation is recommended, this evidence could support a broader use of MI in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 1×
“Furthermore, a crucial role of MI in preventing the ovary hyperstimulation syndrome, during assisted reproductive technology protocol, has also been proposed [10,11].”
BackgroundRetractedEffects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Unfer, V., Carlomagno, G., Dante, G., & Facchinetti, F. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650660 · Cited by 201
Self-citationPabla, D., Akhlaghi, F., & Zia, H. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.10.008 · Cited by 124 · cited 1×
“Development of soft gelatin (soft gel) capsules is of growing interest and several studies report the ability to perform a uniform, faster and enhanced absorption compared to other oral forms [14-17].”
Background
Cited by
Inositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154
“Based on this evidence, myo-Ins was manufactured in the form of a soft gel capsule, resulting in improved gastrointestinal absorption that allows a reduction of the administered dose by one-third compared to the powdered form to achieve the same circulating inositol level, and at the same time overcoming the dose-depe…”
BackgroundSelf-citation(2012) · PubMed · Cited by 111
Reflections on inositol(s) for PCOS therapy: steps toward success
Nestler, J. E., & Unfer, V. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1054802 · Cited by 106
“At this juncture, it was incumbent to determine the physiological concentrations of MI and DCI in plasma in normal women to identify the presumably optimal clinical dosage [28].”
BackgroundSelf-citationUnfer, V., Carlomagno, G., Papaleo, E., Vailati, S., Candiani, M., & Baillargeon, J.-P. (2014) · Reproductive Sciences · doi:10.1177/1933719113518985 · Cited by 105
“Sample Analysis Both MI and DCI were determined as previously described.(20) Quantification of MI and DCI was performed by Chelab Pharma Division (Treviso, Italy) using gas chromatography– mass spectrometry (GC-MS) analysis after extraction with organic solvents and derivatization.”
MethodGünalan, E., Yaba, A., & Yılmaz, B. (2018) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.2018.0077 · Cited by 74
Metadata
- Authors
- Carlomagno, G., De Grazia, S., Unfer, V., & Manna, F.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa Healthcare
- Published
- 2012-02-20
- Volume
- 9
- Issue
- 3
- Pages
- 267-271
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W1974985724
- Cited by
- 41
- References
- 3
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. https://app.cochat.ai/papers/10.1517/17425247.2012.662953
- The paper
- Carlomagno, G., De Grazia, S., Unfer, V., & Manna, F. (2012). Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opinion on Drug Delivery. https://doi.org/10.1517/17425247.2012.662953
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.